TIA offers access to advanced preclinical disease models in NATA-accredited facilities. With a particular expertise and experience in the field of pain, the services can be used to screen new molecules for analgesic activity and to probe the pathobiology of individual human pain conditions. The accredited mature of the facilities means that the resulting data is investor- and regulator-ready.